Every year there is always a lot of noteworthy news and information about hepatitis C, and the trend continued in 2017.
The recent steep increase in cases of acute hepatitis C virus infection, associated with increases in opioid injection, could have devastating long-term consequences.
Screening of people at risk for HCV is insufficient. Access to care and treatment is inadequate. In short, we need to increase our education efforts.
A study of people with HIV and hepatitis C co-infection finds that limited access to food is associated with higher levels of HIV in the blood and 10% fewer CD4+ immune cells.
As one of the few global health threats with easy solutions, why aren't we seeing an impact on the viral hepatitis epidemic?
According to a new Swiss study, uptake of anti-hepatitis C therapy by people coinfected with HIV rose dramatically with the advent of direct-acting antivirals (DAAs), especially second-generation DAAs.
The recent approval of a less expensive drug that generally cures hepatitis C in just eight weeks may make it easier for more insurers and correctional facilities to expand treatment.
"There are many interrelated epidemics within the 'opioid syndemic,'" Thomas J. Stopka writes. "Together, they make up perhaps the biggest public health challenge in the U.S. since the advent of the AIDS epidemic."
"Many of us rightly focus on testing, surveillance and linkage to care," Matthew Zielske writes. "Education often comes as an addendum to any of these things, but hardly ever stands alone."